Unfortunately India have a unique attitude to patents, I've C&P'd the relevant text in this interview, ambiguous about BTA royalty.
Multinational Monitor:The Tamiflu Manufacturing Controversy MAR/APR 2006
Dr. Yusuf Hamied is the chair of Cipla, the Indian generic drug manufacturer
Hamied: We are definitely going to produce, and are producing already, zanamavir as an alternative. That is the inhaled product of Biota in Australia, which was licensed to GlaxoSmithKline.
MM: They are not complaining about your production?
Hamied: They cannot, because the product was patented in 1993. The patent for that does not count in India.
MM: Is it correct that GlaxoSmithKline said that even where they claim a patent, they will not try to enforce it?
Hamied: I have no idea.
It is not their patent. It is a patent of Biota in Australia. Glaxo pays them a royalty.
Like oseltamivir is not a patent of Roche, it is a patent of Gilead. Roche is paying Gilead a royalty, and I am also prepared to pay a royalty on valid patents, so what is the big deal?
http://www.multinationalmonitor.org/mm2006/032006/interview-hamied.html
- Forums
- ASX - By Stock
- BTA
- glaxosmithkline update: influenza a (h1n1)
glaxosmithkline update: influenza a (h1n1), page-5
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BTA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, CEO
James Graham
CEO
Previous Video
Next Video
SPONSORED BY The Market Online